Navigation Links
RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
Date:7/8/2011

NATICK, Mass., July 8, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce the opening of another state of the art facility in Greece for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

The Company's treatment for congestive heart failure is administered at the Metropolitan Hospital in Athens, which is part of the PERSEUS Heath Care Group.  Greece is a convenient location for patients living in Europe and offers patients an additional location where the company's autologous stem cell treatments are permitted.

About RegenoCELL Therapeutics, Inc.

RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients.  The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments.  Through its wholly owned foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.

Cardiac Disease

There are therapies to treat congestive heart failure.  But there comes a treatment point when the only option may be a heart transplant.  Over 25,000 people are on the transplant lists but fewer than 2,500 receive one.  The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.  

Peripheral Artery Disease

The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.

Since 2005, the company's stem cell therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  A half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel.  There the patient's stem cells are extracted and grown from tens of thousands into many millions.  The stem cells are primed for angiogenesis or blood vessel formation.  The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catherization laboratory in a procedure similar to angioplasty.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our inability to predict the extent of our future losses or if or when we will become  profitable; (viii) our ability to protect our intellectual property rights; and, (ix) intense competition.  The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on 'From 10-Q for the quarter ended March 31, 2011.

Contact: James Mongiardo, 508-647-4065, jmongiardo@regenocell.com


'/>"/>
SOURCE RegenoCELL Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
(Date:2/11/2016)... , February 11, 2016 ... ("PositiveID" or "Company") (OTCQB: PSID), a life sciences ... that its Thermomedics subsidiary, which markets the Caregiver® ... growth plan in January 2016, including entering into ... sequential monthly sales growth, and establishing several near-term ...
Breaking Biology Technology:
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market ... iris recognition is more widely accepted for ... with both fingerprint and iris recognition technology ... user to avoid purchasing two individual biometrics ...
(Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Facial Recognition Market ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ... Market 2016-2020" report to their offering. ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ...
(Date:2/3/2016)... -- Vigilant Solutions announces today that the ... solved two recent hit-and-run cases with the ... Solutions. Brian Wenberg explains, "I was ... out of a convenience store and witnessed an elderly male back out ... his vehicle and leaving the scene.  In his statement ...
Breaking Biology News(10 mins):